| Date | Title | Description | |
|---|---|---|---|
| 26 Jul 2023 | On P&L | The Company releases the press release related to the first half 2023 financial results | Download |
| 26 Jul 2023 | On P&L | The Company releases the first half 2023 financial results presentation | Download |
| 26 Jul 2023 | On buy-back programmes | The Company reports the commencement, effective as of today, 26 July 2023, of a share buyback program. | Download |
| 10 May 2023 | On P&L | The Company releases the first quarter 2023 financial results presentation | Download |
| 10 May 2023 | On P&L | The Company releases the press release related to the first quarter 2023 financial results | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 23 Feb 2022 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors | Download |
| 23 Feb 2022 | Annual Corporate Governance Report | ROVI releases the 2021 Annual Corporate Governance Report | Download |
| 21 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 | Download |
| 15 Feb 2022 | On business and financial situation | ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. | Download |
| 14 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Feb 2019 | Información sobre resultados | ROVI releases the presentation related to the full year 2018 results | Download |
| 26 Feb 2019 | Información sobre resultados | ROVI releases the press release related to the full year 2018 results | Download |
| 15 Feb 2019 | Others on business performance and financial information | ROVI acquires rights to Dexchlorpheniramine Maleate in the Spanish and French markets | Download |
| 09 Jan 2019 | Others on business performance and financial information | ROVI informs about the adquisition of Falithrom® for the German market | Download |
| 08 Jan 2019 | Liquidity contracts and specialists | Liquidity contract: transactions conducted in the fourth quarter of 2018 | Download |